In this section
- Antibody specificity and characterisation
- Biomarker discovery
- Drug Target Discovery (Antigen discovery)
- Epitope mapping
- Gene expression profiling
- Human glycomics
- Plant glycomics
- Hybridoma screening
- Label-free (e.g. SPRi)
- Microbiome analysis
- Point of care diagnostics
- Reverse phase protein arrays (RPPA)
- Single cell analysis
- Small Molecule Screening
High-throughput biologics screening
Potential drug targets arising from the explosion in proteomics research have increased in tandem with high-throughput biologics synthesis. Traditional methods such as enzyme-linked immunosorbent assays (ELISA) are labour-intensive and require large sample volumes, whereas mass spectrometry-based technologies can lack sensitivity and may yield variable results. Whilst both are useful tools in their own right, critical success factors for drug discoverers dictate that screening methods should be cost-effective, highly multiplex and fast.
In response to demands for high-throughput biologics screening, Arrayjet has developed a novel assay that is:
- more sensitive than ELISA
- simpler than mass spectrometry
- higher throughput than cellular-based assays
Utilising Arrayjet inkjet technology, ArrayPlex™ maximises sample conservation (typically only around 20 µL of each sample is used to generate up to two million data points), making it ideal for rapidly identifying new affinity reagents in a very cost-effective manner.
By outsourcing discovery projects to Arrayjet scientists and using a proven screening assay, customers can be assured that their assay has minimal risk. The identity of molecular antigens is not required and the screening service is fully automated, vastly accelerating the growth of pre-clinical pipelines.